Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

SAN DIEGO, April 1, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with two programs in clinical-stage development, today announced the departure of Dr. Brendan Eckelman, co-founder and Chief Scientific Officer (CSO) and the appointments of Dr. Carlos Bais and David Matly to CSO and President, respectively. About Mr. Matly Mr. Matly joined Inhibrx, Inc. in October 2021 from Novartis, where he most recently served as the ...